Physician profile
Rita Ceponiene
NPI 1356584015
$2,197.22
in general payments reported to CMS, 2019-2025
10 companies · $379 in 2025
The $379 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $259 · 2020: $34.05 · 2022: $124 · 2023: $1,402 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $725 · Food and Beverage: $706 · Consulting Fee: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $725.00 |
| Food and Beverage | $705.91 |
| Consulting Fee | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,148.15 | 2023-2025 | Activa PC, Percept PC Brainsense |
| Abbott Laboratories | $556.20 | 2019-2023 | Infinity |
| Boston Scientific Corporation | $178.06 | 2025 | General - Dbs |
| Eisai INC. | $123.64 | 2022 | |
| Abbvie INC. | $81.26 | 2025 | |
| Acadia Pharmaceuticals INC | $31.75 | 2019 | |
| Acorda Therapeutics, INC | $23.45 | 2019 | |
| Lundbeck LLC | $20.66 | 2019 | |
| Sunovion Pharmaceuticals INC. | $17.52 | 2020 | |
| Amneal Pharmaceuticals LLC | $16.53 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rita Ceponiene listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.